These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

679 related items for PubMed ID: 23306360

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium.
    Bilcke J, Marais C, Ogunjimi B, Willem L, Hens N, Beutels P.
    Vaccine; 2012 Jan 11; 30(3):675-84. PubMed ID: 22120193
    [Abstract] [Full Text] [Related]

  • 4. A systematic review of the cost effectiveness of herpes zoster vaccination.
    Szucs TD, Pfeil AM.
    Pharmacoeconomics; 2013 Feb 11; 31(2):125-36. PubMed ID: 23335045
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years.
    Le P, Rothberg MB.
    Ann Intern Med; 2015 Oct 06; 163(7):489-97. PubMed ID: 26344036
    [Abstract] [Full Text] [Related]

  • 7. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.
    Ultsch B, Weidemann F, Reinhold T, Siedler A, Krause G, Wichmann O.
    BMC Health Serv Res; 2013 Sep 26; 13():359. PubMed ID: 24070414
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of vaccination against herpes zoster.
    de Boer PT, Wilschut JC, Postma MJ.
    Hum Vaccin Immunother; 2014 Sep 26; 10(7):2048-61. PubMed ID: 25424815
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany.
    Préaud E, Uhart M, Böhm K, Aidelsburger P, Anger D, Bianic F, Largeron N.
    Hum Vaccin Immunother; 2015 Sep 26; 11(4):884-96. PubMed ID: 25933182
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review.
    Kawai K, Preaud E, Baron-Papillon F, Largeron N, Acosta CJ.
    Vaccine; 2014 Mar 26; 32(15):1645-53. PubMed ID: 24534737
    [Abstract] [Full Text] [Related]

  • 11. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.
    Brisson M, Pellissier JM, Camden S, Quach C, De Wals P.
    Hum Vaccin; 2008 Mar 26; 4(3):238-45. PubMed ID: 18382137
    [Abstract] [Full Text] [Related]

  • 12. Cost effectiveness of herpes zoster vaccine in Canada.
    Najafzadeh M, Marra CA, Galanis E, Patrick DM.
    Pharmacoeconomics; 2009 Mar 26; 27(12):991-1004. PubMed ID: 19908924
    [Abstract] [Full Text] [Related]

  • 13. Potential cost-effectiveness of adjuvanted herpes zoster subunit vaccine for older adults in Hong Kong.
    You JHS, Ming WK, Lee CF, Tsang OT, Chan PK.
    Vaccine; 2018 Jul 25; 36(31):4610-4620. PubMed ID: 29958739
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan.
    Hoshi SL, Kondo M, Okubo I.
    Vaccine; 2017 May 31; 35(24):3264-3271. PubMed ID: 28479176
    [Abstract] [Full Text] [Related]

  • 15. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
    McGirr A, Van Oorschot D, Widenmaier R, Stokes M, Ganz ML, Jung H, Varghese L, Curran D.
    Appl Health Econ Health Policy; 2019 Oct 31; 17(5):723-732. PubMed ID: 31250218
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines.
    de Boer PT, van Lier A, de Melker H, van Wijck AJM, Wilschut JC, van Hoek AJ, Postma MJ.
    BMC Med; 2018 Dec 06; 16(1):228. PubMed ID: 30518427
    [Abstract] [Full Text] [Related]

  • 17. The use of Zostavax in Spain: the economic case for vaccination of individuals aged 50 years and older.
    Lopez-Belmonte JL, Cisterna R, Gil de Miguel A, Guilmet C, Bianic F, Uhart M.
    J Med Econ; 2016 Jun 06; 19(6):576-86. PubMed ID: 26808422
    [Abstract] [Full Text] [Related]

  • 18. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium.
    Annemans L, Bresse X, Gobbo C, Papageorgiou M.
    J Med Econ; 2010 Jun 06; 13(3):537-51. PubMed ID: 20707768
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Hornberger J, Robertus K.
    Ann Intern Med; 2006 Sep 05; 145(5):317-25. PubMed ID: 16954357
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of a herpes zoster vaccination program among the French elderly people.
    Belchior E, Lévy-Bruhl D, Le Strat Y, Herida M.
    Hum Vaccin Immunother; 2016 Sep 05; 12(9):2378-82. PubMed ID: 27484158
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.